Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

45P - In silico transcriptomic mapping of Notch Biological Pathway in Luminal Breast Cancer

Date

15 Oct 2022

Session

Poster display session

Presenters

Katerin Rojas Laimito

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

K.I. Rojas Laimito1, M..R. Martin2, F. Rojo3, A. Gámez-Pozo4, F..J. De castro2, E. Filipovich Vegas2, J. Ceballos Viro5, J.E. Ales Martínez6

Author affiliations

  • 1 Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona/ES
  • 2 Hospital Nuestra Señora de Sonsoles, Avila/ES
  • 3 University Hospital Fundacion Jimenez Diaz, Madrid/ES
  • 4 Instituto de Investigación La Paz (IdiPAZ),, Madrid/ES
  • 5 Hospital Nuestra Señora de Sonsoles, Ávila/ES
  • 6 Hospital Nuestra Señora de Sonsoles, 05004 - Ávila/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 45P

Background

In many solid Notch pathway is deregulated, affecting most hallmarks in cancer. Notch pathway plays a key role in cellular differentiation and its dysregulations contributes to carcinogenesis. Notch gene expression is frequently altered in breast cancer (BC) and exists ample evidence of the role of Notch in tumor formation, progression and resistance to treatment in BC. A less explored function of Notch pathways in cancer is their role in leukocyte homing and activation. Understanding their role and relationship with immune infiltrates is an area of interest in cancer research.

Methods

The expression of four different Notch genes (Notch1, Notch2, Notch3 and Notch4) was explored in relation with A luminal BC patient outcome using transcriptomic data (Affymetrix dataset, exploratory cohort) and the METABRIC study (validation cohort). The TIMER online tool was used to explore the association of the identified notch and immune infiltration, and the TCGA and METABRIC studies to analyze the correlation between notch1 - 4 expression and genomic signatures of immune activation.

Results

We identified 2 individual genes called Notch1 and Notch2, which predict favorable prognosis in luminal A breast cancer. Their expression positively correlated with the presence of immune infiltrates within the tumor (dendritic cells, CD4+ T cells, neutrophils, CD8+ T cells and B cells), with markers of T cell activation and antigen presentation, and with gene signatures of immune surveillance (cytotoxic T lymphocyte activation and IFN gamma signature). By contrast Notch3 and Notch4 which predicted for detrimental outcome were not associated with any of these parameters.

Conclusions

Our analysis identifies a Notch signature composed of 2 genes with potential to recognize immune infiltrated and activated A luminal phenotype BC with favorable prognosis.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.